Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy

@article{Jung2009DiseasespecificRF,
  title={Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy},
  author={Tatjana I. Jung and Falk Hoffmann and Gerd Glaeske and Dieter Felsenberg},
  journal={Journal of Cancer Research and Clinical Oncology},
  year={2009},
  volume={136},
  pages={363-370}
}
  • Tatjana I. Jung, Falk Hoffmann, +1 author Dieter Felsenberg
  • Published 2009
  • Medicine
  • Journal of Cancer Research and Clinical Oncology
  • PurposeOsteonecrosis of the jaw (ONJ) presents a severe side-effect of intravenous bisphosphonate (i.v. BP) treatment; yet, the pathoethiological influence of the underlying disease which indicated that treatment remains unclear.MethodsWe studied a large register of subjects who suffered an ONJ (n = 356) under i.v. BP therapy and characterized them according to underlying diseases and BP intake. By using claims data, we analysed indications in the general public in a cohort of new users of i.v… CONTINUE READING

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 30 CITATIONS, ESTIMATED 56% COVERAGE

    Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.

    VIEW 2 EXCERPTS
    CITES METHODS & BACKGROUND

    FILTER CITATIONS BY YEAR

    2010
    2019

    CITATION STATISTICS

    • 2 Highly Influenced Citations

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 37 REFERENCES

    Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

    VIEW 2 EXCERPTS

    Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?

    VIEW 1 EXCERPT

    Osteonecrosis of the jaw: who gets it, and why?

    VIEW 5 EXCERPTS
    HIGHLY INFLUENTIAL

    Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

    VIEW 2 EXCERPTS

    Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.

    VIEW 3 EXCERPTS